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We are most grateful to Eugene Koonin for having accepted to write for Biology 
& Philosophy a target paper on such a major topic in current biology as CRISPR-
Cas (CRISPR-Cas stands for “Clustered Regularly Interspaced Short Palindromic 
Repeats”). There is indeed little doubt that the characterization of the CRISPR-Cas 
systems and their mechanisms constitutes a ground-breaking discovery in recent 
biological and biomedical sciences, from basic microbiology to technological 
applications (Doudna and Charpentier 2014). One sign of recognition among many 
has come from the leading journal Science, which chose CRISPR-Cas as its 2015 
“breakthrough of the year” (McNutt 2015), described as “poised to revolutionize 
research” because of its role in genome editing.
In the beginning of the 2000s, CRISPR-Cas was identified as a form of immunity 
in Archaea and bacteria (Mojica et al. 2005; Pourcel et al. 2005; Bolotin et al. 2005; 
Makarova et al. 2006; Barrangou et al. 2007). This fundamental work followed dec-
ades of investigations, by many researchers from several laboratories around the 
world, that partly anticipated this discovery, making the history of CRISPR-Cas par-
ticularly intricate (Morange 2015a, b). In a nutshell, CRISPR-Cas makes it possible 
for many prokaryotes to detect and eliminate viruses (known as phages, in the case 
of bacteria) and to respond more efficiently if the same virus is encountered for a 
second time. Taken together, these results led to the now commonly accepted con-
cept that CRISPR-Cas is a prokaryotic adaptive immune system, endowed with a 
form of immune “memory” (Hille et al. 2018).
More recently, CRISPR-Cas has been developed into an arsenal of novel, power-
ful tools for genome manipulation (Cong et al. 2013; Doudna and Charpentier 2014; 
Komor et al. 2017). By now, CRISPR-Cas has been widely adopted as a gene-editing 
tool in labs across the world, and many students learn how to use it. Yet, this fantas-
tic toolkit also raises several important issues. First, many researchers are concerned 
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about the potentially dramatic consequences of misguided use of CRISPR-Cas, 
especially in the situation when it could alter human DNA in a heritable way. At 
an international meeting in Napa, California, in 2015, a group of experts, includ-
ing the world-leading CRISPR researcher Jennifer Doudna, called for a moratorium 
on using CRISPR-Cas9 technology for any modification of the germline genome in 
humans (Baltimore et al. 2015). In 2016, an advisory committee at the US National 
Institutes of Health (NIH) approved the first human trial to use CRISPR gene edit-
ing. The goal of this trial is to edit the patient’s own T cells via CRISPR-Cas9 tech-
nology as a part of a cancer therapy protocol (Reardon 2016). Second, part of the 
CRISPR-Cas research community has been plagued with disagreements over pat-
ents, with huge financial interests (Contreras and Sherkow 2017; Ledford 2018). 
It comes as no surprise, therefore, that, at present, CRISPR-Cas technologies are 
actively discussed by bioethicists, regulatory bodies, and the public more generally 
[e.g., (Belluck 2017)].
Eugene Koonin is the ideal person for presenting CRISPR-Cas to a philosoph-
ical audience. Koonin is a prominent biologist and an expert in evolutionary and 
computational biology. His research spans an expansive range of subjects, from 
genome sequencing to comparative genomics, protein classification, horizontal gene 
transfer (and related issues around the “tree of life”), identification of giant viruses, 
and virus classification, among many other areas. Koonin’s work also has a strong 
conceptual and philosophical dimension, as illustrated by his book, The Logic of 
Chance (Koonin 2011), many of his scientific papers [e.g., (Koonin and Wolf 2010; 
Koonin and Krupovic 2015)], and also by his publications in philosophy of science 
journals [e.g., (Koonin and Starokadomskyy 2016)] or in collaboration with philos-
ophers (O’Malley and Koonin 2011). Furthermore, and most crucially for the pre-
sent issue of Biology & Philosophy, Koonin has been a major actor in the discovery, 
characterization, and classification of CRISPR-Cas systems [e.g., (Makarova et al. 
2001a, b2002, 2006, 2015; Shmakov et  al. 2015; Mohanraju et  al. 2016; Koonin 
et al. 2017)].
In the target paper presented in this issue and entitled “CRISPR: a new principle 
of genome engineering linked to conceptual shifts in evolutionary biology”, Koonin 
argues that CRISPR-Cas systems offer to date the best instance of a mechanism of 
Lamarckian evolution. He defines such Lamarckian evolution as the generation of 
heritable, adaptive genomic changes in response to encounters with external factors 
(he also talks about “Inheritance of Acquired adaptive Characteristics”, or “IAC”). 
In the case of CRISPR-Cas, the external factor corresponds to foreign nucleic acids 
(phages, plasmids, and so on). He describes the CRISPR-Cas system in prokary-
otes as an adaptive immune system, based on self–nonself discrimination. He also 
examines the connections between CRISPR-Cas and programmed cell death and 
dormancy induction in microbes, two phenomena possibly associated with a form 
of evolutionary “altruism”. Finally, he explores the role that mobile genetic elements 
(MGE) played in the origin of various components of CRISPR-Cas systems.
Koonin’s paper is followed by a series of selected commentaries, written by biol-
ogists of different backgrounds and philosophers of biology. In the first commen-
tary, “Mutationism, not Lamarckism, captures the novelty of CRISPR-Cas”, Jeremy 
Wideman, Andrew Inkpen, Ford Doolittle, and Rosemary Redfield (Wideman et al. 
1 3
Philosophy of CRISPR-Cas: Introduction to Eugene Koonin’s… Page 3 of 5 16
2018) reject Koonin’s characterization of CRISPR-Cas as a Lamarckian mode of 
evolution. Instead, they suggest that the CRISPR-Cas system is better conceptual-
ized as a process of directed mutations, that is, mutations (rather complex ones in 
the case of CRISPR-Cas, because they are based on spacer acquisition) that are not 
random with respect to the potential benefit. In their view, such a description enables 
one to situate CRISPR-Cas more accurately within debates between mutationists 
and neo-Darwinists,1 as it constitutes a strong objection against the neo-Darwinist 
view that the cause of a new mutation is not influenced by its benefit or cost, rather 
than in the context of Lamarck’s view in the early 1800s.
In another quite critical commentary, entitled “Striving for clarity about the 
“Lamarckian” nature of CRISPR-Cas systems”, Sam Woolley, Emily C. Parke, 
David Kelley, Anthony M. Poole, and Austen Ganley (Woolley et  al. 2018) make 
three main claims against the views expressed in Koonin’s paper. First, according to 
the authors, Koonin sometimes makes a confusion between the system of CRISPR-
Cas as such and the mechanism that it uses. For them, an accurate description is that 
the CRISPR-Cas system uses two mechanisms (acquisition of pathogen DNA and 
transcription/targeting), and the only question is whether the mechanism of acqui-
sition of pathogen DNA is Lamarckian or not. Second, after distinguishing three 
meanings of “Lamarckism”, they reject the view that the CRISPR-Cas system would 
be “Lamarckian”, particularly because it does not exhibit the kind of teleological 
connotation usually associated by Lamarckism. Finally, they propose that a key fea-
ture of CRISPR-Cas systems is that they do hold the potential for a genuinely non-
Darwinian, directed evolution, but one that differs from what Koonin describes, and 
that is based instead on the use of CRISPR-Cas as a human gene-editing tool.
In “A Use/Disuse Paradigm for CRISPR-Cas Systems”, Sophie Veigl (2018) 
narrows down the criteria for counting as a “Lamarckian” phenomenon, and then 
proposes that interference-driven spacer acquisition (IDSA) could be seen as an 
instantiation of a truly Lamarckian paradigm. Furthermore, she considers whether 
Lamarckian inheritance and canonical inheritance can be understood within the 
philosophical context of theoretical pluralism.
In her commentary, entitled “Lamarckian realities: the CRISPR-Cas system and 
beyond”, Jablonka (2018) proposes to contextualize and extend Koonin’s claim that 
the CRISPR-Cas system should be considered as “Lamarckian”. She offers a con-
ceptually and historically enriched characterization of “Lamarckism” and “quasi-
Lamarckism” [see also (Jablonka and Gissis 2011)]. She agrees that CRISPR-Cas 
offers to date a prime example of a phenomenon of inheritance of acquired genomic 
characters. Additionally, she emphasizes how Lamarckian and quasi-Lamarckian 
processes, including CRISPR-Cas, influence evolvability.
In “CRISPR-Cas Changing Biology?”, Baxter (2018) focuses on the human 
dimension of recent CRISPR-Cas research. She argues that CRISPR-Cas technolo-
gies are not “natural” genome editing systems, but, at least in part, human artefacts. 
Moreover, she emphasizes that, in a case such as CRISPR-Cas systems, the tradi-
tional distinction between fundamental and applied research is blurred.
1 On these debates, see (Gayon 1998; Beatty 2016).
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Finally, Thomas Pradeu and Jean-François Moreau, in “CRISPR-Cas immu-
nity: Beyond nonself and defence” (Pradeu and Moreau 2018), propose to adopt an 
extended view of CRISPR-Cas immunity by arguing that CRISPR-Cas includes, but 
cannot be reduced to, defence against nonself. First, CRISPR-Cas systems can target 
endogenous elements and tolerate exogenous elements. Second, CRISPR-Cas-based 
immunity concerns activities that go beyond defence, such as DNA repair. In being 
not reducible to immunity against nonself, CRISPR-Cas is similar to other forms of 
immunity across the living world.
This series of papers ends with Eugene Koonin’s response to commentaries. In 
addressing in detail virtually all the remarks and objections made by the different 
commentators, Koonin offers an even richer and more precise picture of his views 
about CRISPR-Cas. We would like to thank once again Eugene Koonin for this 
inaugural target paper as well as all the commentators for their excellent work on a 
highly exciting topic in current biology which will undoubtedly continue to instigate 
vigorous debates among biologists and philosophers alike in the years to come.
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